MedTrace Logo

Effect of Coffeeberry on Mood and Cognitive Performance

NCT04975802 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-03-24

No results posted yet for this study

Summary

The primary aim of this randomised, double-blind, placebo-controlled, cross-over study is to assess the short-term cognitive effects of two beverages containing 100 and 300 mg coffeeberry extract (obtained from the fruit of the coffee plant (Coffea arabica) compared to a placebo beverage. The trial will utilise the COMPASS cognitive assessment system and cognitive demand battery (CDB) and mood visual analogue scales (VAS) with assessments taking place at baseline, 60- and 120-minutes post treatment, on four separate testing days separated by 7 days. A treatment containing 75 mg caffeine will be used as a positive control to document participants' responsiveness to an established psychostimulant.

Conditions

  • Mental Fatigue
  • Alertness
  • Mood
  • Cognition

Interventions

OTHER

Placebo

10 oz (296 ml) cherry flavored still beverage

DIETARY_SUPPLEMENT

Coffeeberry

10 oz (296 ml) cherry flavored still beverage

DIETARY_SUPPLEMENT

Caffeine

10 oz (296 ml) cherry flavored still beverage

Sponsors & Collaborators

  • PepsiCo Global R&D

    lead INDUSTRY

Principal Investigators

  • Philippa Jackson, PhD · Northumbria University Newcastle, UK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-05
Primary Completion
2022-02-04
Completion
2022-02-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975802 on ClinicalTrials.gov